Skip to main content

Kalaris Therapeutics, Inc.

KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001754068

No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Kalaris Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of KLRS: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders9490−4
Shares54.0M53.7M−278.0K (−0.5%)
Value$183.6M$115.5M−$68.1M (−37.1%)

New holders (14)

Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to KLRS in Q3 2023
InstitutionSharesValue% of portfolio
XTX Topco Ltd84,049$180.7K0.03%
Verition Fund Management LLC67,730$145.6K0.00%
Jane Street Group, LLC48,376$104.0K0.00%
Jump Financial, LLC36,396$78.3K0.00%
Two Sigma Investments, LP34,421$74.0K0.00%
SG Americas Securities, LLC23,293$50.0K0.00%
Clear Street Markets LLC20,076$43.0K0.03%
Advisor Group Holdings, Inc.15,000$32.3K0.00%
Graham Capital Management, L.P.11,962$25.7K0.00%
Ameriprise Financial Inc10,720$23.0K0.00%
Quadrant Capital Group LLC3,030$6.51K0.00%
Simplex Trading, LLC1,665$3.00K0.00%
Signaturefd, LLC625$1.34K0.00%
US Bancorp442$9500.00%

Sold out (18)

Institutions that held Kalaris Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.